OpenAI Quietly Lists a Second GPT-Rosalind Model for Life Sciences
OpenAI has quietly added a second GPT-Rosalind model, gpt-rosalind-discovery, to its API pricing page without a blog post, system card, or help article.
The listing appears under a new "Life sciences models" section, where gpt-rosalind-discovery sits beside gpt-rosalind-research. Both carry identical pricing: $5 per million input tokens, $0.50 per million cached input tokens, and $25 per million output tokens. Billing for gpt-rosalind-research began October 5, 2026, and cache-write pricing does not apply. Access remains restricted to approved internal research through OpenAI's trusted-access program, with data residency endpoints adding a 10% uplift for eligible models released on or after March 5, 2026.
OpenAI has not described what gpt-rosalind-discovery does. The name points toward drug discovery, and the company's April introduction of GPT-Rosalind framed it as a frontier reasoning model for biology, drug discovery, and translational medicine, with Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific among early partners. The help center describes the current model as most useful for early discovery and hypothesis generation—target biology, literature synthesis, omics interpretation. A variant tuned for target identification or molecular design would fit, but that remains inference.
OpenAI has also stated that "all eligible organizations will continue to get access to the latest GPT-Rosalind models as they're released," confirming a planned family rather than a single model. Context: GPT-Rosalind left research preview on September 11 and opened to eligible organizations worldwide through trusted access; published pricing took effect October 5. The latest version, GPT-Rosalind-5.5, is trained on GPT-5.5 and, per its system card, trained not to refuse sophisticated biology questions, with gated access as the primary safeguard—the same approach OpenAI used for GPT-5.4-Cyber.
OpenAI often lists models on the pricing page shortly before announcing them, so a formal announcement may be imminent. The open questions are whether this is a separately trained model or a tuned variant of the research model, and whether trusted-access requirements change.